(2026). Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: A partitioned survival analysis. Health Economics Review.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Cost-utility of First-line Dostarlimab Plus Carboplatin-paclitaxel Compared with Placebo for Patients with PA/rEC: A Partitioned Survival Analysis."
Health Economics Review 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Cost-utility of First-line Dostarlimab Plus Carboplatin-paclitaxel Compared with Placebo for Patients with PA/rEC: A Partitioned Survival Analysis."
Health Economics Review, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.